Massive 'rerating' of Biotech industry — by 2026, generative biology achieves its 'De Novo' moment where an AI-designed drug candidate triggers multi-billion-dollar partnerships; AI expands Total Addressable Market (TAM) of gene editing by 100x, moving...

Massive 'rerating' of Biotech industry — by 2026, generative biology achieves its 'De Novo' moment where an AI-designed drug candidate triggers multi-billion-dollar partnerships; AI expands Total Addressable Market (TAM) of gene editing by 100x, moving technology from treating rare diseases to mainstream cardiovascular prevention. | First >$1B AI-designed drug partnership

Key catalyst: First >$1B AI-designed drug partnership

Watch events: First AI-designed drug Phase 3 partnership

MS biotech-AI rerating research 2025-2026; AI-designed drug partnerships (Xaira, Recursion, Isomorphic) scaling. 100x TAM expansion aggressive.

Beneficiaries (19)

{
  "nia": false,
  "qty": "100x gene-editing TAM",
  "mode": "FORECAST",
  "role": "Cited-Firm",
  "context": "Second MS biotech framing. Specific 'De Novo moment' coinage + 100x gene-editing TAM expansion claim.",
  "to_year": 2030,
  "conv_cues": "institutional research; coined De Novo framing; 100x multiple",
  "direction": "NUMERIC_TARGET",
  "from_year": 2026,
  "timeframe": "2026-2030",
  "conv_level": "HIGH",
  "milestones": [
    {
      "kind": "llm_pre_event",
      "label": "First single AI-designed drug partnership exceeds $1B (validates 'De Novo' moment)",
      "source": "https://intuitionlabs.ai/articles/lilly-insilico-ai-drug-discovery-deal",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -7,
      "source_id": null,
      "confidence": 0.9,
      "expected_date": "2026-08-16",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2026-12-31",
        "from": "2026-04-01"
      },
      "measurement_criterion": "Already partially validated by 2026 deals: Lilly-Insilico $2.75B (Mar 2026), Lilly-Isomorphic $1.75B, Bayer-Recursion $1.5B, Novo-Valo $2.76B; criterion checks for one announced >=$1B AI-designed-asset deal in any 2026 quarter"
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q1 window check-in (25%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -6,
      "source_id": null,
      "expected_date": "2026-12-12",
      "observed_date": null
    },
    {
      "kind": "llm_pre_event",
      "label": "Rentosertib or other AI-designed drug reads out positive Phase III result",
      "source": "https://www.humai.blog/ai-discovered-drugs-reach-phase-iii-and-2026-will-determine-whether-all-the-promises-were-real/",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -5,
      "source_id": null,
      "confidence": 0.55,
      "expected_date": "2027-09-16",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2028-12-31",
        "from": "2026-06-01"
      },
      "measurement_criterion": "Insilico Rentosertib or any other AI-discovered drug publishes positive Phase III pivotal trial readout in peer-reviewed journal or company press release"
    },
    {
      "kind": "quartile_checkpoint",
      "label": "Q2 window check-in (50%)",
      "status": "pending",
      "weight": 0.05,
      "ordinal": -4,
      "source_id": null,
      "expected_date": "2027-11-22",
      "observed_date": null
    },
    {
      "kind": "llm_post_event",
      "label": "Biotech sector forward P/E or median EV/Revenue rerates above 5y average per XBI/Bloomberg",
      "source": "https://www.drugpatentwatch.com/blog/ai-driven-drug-discovery-transforming-the-landscape-of-pharmaceutical-research/",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -3,
      "source_id": null,
      "confidence": 0.5,
      "expected_date": "2028-01-30",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2029-06-30",
        "from": "2026-09-01"
      },
      "measurement_criterion": "XBI sector index forward P/E or median price-to-sales reranks above 5-year average sustained for >=2 quarters, signaling market-recognized rerating"
    },
    {
      "kind": "llm_pre_event",
      "label": "Gene-editing TAM expansion: first cardiovascular-prevention gene therapy enters Phase III",
      "source": "https://biomednexus.com/ai-drug-discovery-companies-clinical-candidates-2026/",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -2,
      "source_id": null,
      "confidence": 0.6,
      "expected_date": "2028-07-01",
      "research_origin": "training",
      "expected_date_range": {
        "to": "2029-12-31",
        "from": "2027-01-01"
      },
      "measurement_criterion": "Verve Therapeutics, Beam Therapeutics, or comparable platform begins pivotal Phase III for cardiovascular-prevention indication (e.g., PCSK9 base editing) per ClinicalTrials.gov filing"
    },
... (truncated)